PL2556091T3 - Przeciwciało rozpoznające ludzki czynnik hamujący białaczkę (LIF) i zastosowanie przeciwciał anty-LIF w leczeniu chorób związanych z niepożądaną proliferacją komórkową - Google Patents

Przeciwciało rozpoznające ludzki czynnik hamujący białaczkę (LIF) i zastosowanie przeciwciał anty-LIF w leczeniu chorób związanych z niepożądaną proliferacją komórkową

Info

Publication number
PL2556091T3
PL2556091T3 PL11715676T PL11715676T PL2556091T3 PL 2556091 T3 PL2556091 T3 PL 2556091T3 PL 11715676 T PL11715676 T PL 11715676T PL 11715676 T PL11715676 T PL 11715676T PL 2556091 T3 PL2556091 T3 PL 2556091T3
Authority
PL
Poland
Prior art keywords
lif
treatment
cell proliferation
diseases associated
inhibitory factor
Prior art date
Application number
PL11715676T
Other languages
English (en)
Inventor
Suarez Joan Seoane
Folgueira Judit Anido
Borderias Andrea Saez
Original Assignee
Fundacio Privada Institut D'investigacio Oncologica De Vall D'hebron (Vhio)
Fundació Privada Institució Catalana De Recerca I Estudis Avançants
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Institut D'investigacio Oncologica De Vall D'hebron (Vhio), Fundació Privada Institució Catalana De Recerca I Estudis Avançants filed Critical Fundacio Privada Institut D'investigacio Oncologica De Vall D'hebron (Vhio)
Publication of PL2556091T3 publication Critical patent/PL2556091T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5415—Leukaemia inhibitory factor [LIF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL11715676T 2010-04-05 2011-04-05 Przeciwciało rozpoznające ludzki czynnik hamujący białaczkę (LIF) i zastosowanie przeciwciał anty-LIF w leczeniu chorób związanych z niepożądaną proliferacją komórkową PL2556091T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10380049A EP2371860A1 (en) 2010-04-05 2010-04-05 Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
EP11715676.0A EP2556091B1 (en) 2010-04-05 2011-04-05 Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation

Publications (1)

Publication Number Publication Date
PL2556091T3 true PL2556091T3 (pl) 2017-04-28

Family

ID=42338260

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11715676T PL2556091T3 (pl) 2010-04-05 2011-04-05 Przeciwciało rozpoznające ludzki czynnik hamujący białaczkę (LIF) i zastosowanie przeciwciał anty-LIF w leczeniu chorób związanych z niepożądaną proliferacją komórkową

Country Status (25)

Country Link
US (3) US8926956B2 (pl)
EP (3) EP2371860A1 (pl)
JP (2) JP6289906B2 (pl)
KR (5) KR20180078352A (pl)
CN (2) CN103797031A (pl)
AU (1) AU2011237922B2 (pl)
BR (1) BR112012025517B1 (pl)
CA (1) CA2797257A1 (pl)
CY (1) CY1119451T1 (pl)
DK (1) DK2556091T3 (pl)
EA (2) EA202092276A3 (pl)
ES (1) ES2608699T3 (pl)
HK (2) HK1208469A1 (pl)
HR (1) HRP20161736T1 (pl)
HU (1) HUE030578T2 (pl)
IL (3) IL222270A (pl)
LT (1) LT2556091T (pl)
MX (2) MX365054B (pl)
PL (1) PL2556091T3 (pl)
PT (1) PT2556091T (pl)
RS (1) RS55539B1 (pl)
SG (1) SG184429A1 (pl)
SI (1) SI2556091T1 (pl)
SM (1) SMT201600468T1 (pl)
WO (1) WO2011124566A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101338533B1 (ko) * 2005-07-19 2013-12-12 스템젠 에스.피.에이. Ｌｉｆ 및 ｂｍｐ에 의한 종양 줄기 세포의 종양발생가능성의 억제
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
US20160237158A1 (en) * 2013-09-23 2016-08-18 Institut National De La Santé Et Da La Recherche Médicale (Inserm) Methods and Compositions for Targeting Tumor Microenvironment and for preventing Metastasis
TWI486172B (zh) * 2013-11-08 2015-06-01 長庚大學 鼻咽癌治療的醫藥
WO2016040657A1 (en) * 2014-09-10 2016-03-17 The Regents Of The University Of California TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES
MX385372B (es) 2015-03-23 2025-03-18 Evestra Inc Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos
EP3173483A1 (en) * 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
AU2017381585B2 (en) * 2016-12-19 2025-02-13 Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats Antibodies against LIF and uses thereof
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
WO2019197903A1 (en) * 2018-04-12 2019-10-17 Mosaic Biomedicals Slu Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer
KR20210008514A (ko) * 2018-05-14 2021-01-22 메디뮨 리미티드 Lif에 대한 항체 및 이의 투여 형태
AU2019291307B2 (en) * 2018-06-18 2024-04-04 Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats Combination of LIF inhibitors and platinum-based antineoplastic agents for use in treating cancer
CN112703202A (zh) * 2018-06-18 2021-04-23 免疫医疗有限公司 用于改善患有癌症的个体对抗lif抗体治疗的反应的方法
WO2021057991A1 (zh) * 2019-09-29 2021-04-01 北京加科思新药研发有限公司 对lif具有特异性的结合分子及其用途
CN111020030A (zh) * 2019-12-03 2020-04-17 中山大学 一种骨肉瘤干细胞标志物及其应用、试剂盒
CN111378036B (zh) * 2020-01-09 2021-08-10 北京浩古元方生物医药科技有限公司 一种抗人白血病抑制因子单克隆抗体的制备方法及其应用
CN112294812B (zh) * 2020-11-18 2022-08-16 新乡医学院 一种小分子抑制剂在制备抗肿瘤药物方面的应用
CN114672460B (zh) * 2021-12-21 2023-06-23 中国人民解放军军事科学院军事医学研究院 一种靶向cd44的异质型cic细胞模型的制备方法及应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB9004890D0 (en) 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
JPH05304986A (ja) 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
AU4231393A (en) 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
WO1993023665A1 (en) 1992-05-15 1993-11-25 Re/Map Incorporated Electromagnetic shielding for a liquid conditioning device
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
DE69635630T2 (de) * 1995-04-24 2006-08-10 Genentech, Inc., South San Francisco Verwendung eines Leukämie-hemmenden Faktor Antagonisten
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
AU2003218456A1 (en) 2002-04-01 2003-10-20 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
EP2236614A3 (en) * 2002-08-15 2011-01-26 Genzyme Corporation Brain endothelial cell expression patterns
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005030803A1 (en) 2003-09-29 2005-04-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
WO2005116204A1 (ja) 2004-05-11 2005-12-08 Rnai Co., Ltd. Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法
EP1612558A1 (en) 2004-06-30 2006-01-04 Academisch Ziekenhuis Leiden Method for detecting gluten
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
JP2010505876A (ja) 2006-10-04 2010-02-25 ザ スクリプス リサーチ インスティテュート ヒトメタニューモウイルスを中和するヒト抗体
CN101440128A (zh) * 2007-11-21 2009-05-27 中国人民解放军第二军医大学 人脑胶质瘤中差异表达的蛋白及其用途
WO2010054499A1 (en) * 2008-11-11 2010-05-20 Telefonaktiebolaget L M Ericsson (Publ) A dpd system with multiple transmitter paths
ES2363358B1 (es) 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
WO2011057144A2 (en) 2009-11-06 2011-05-12 La Jolla Institute For Allergy And Immunology Methods for modulating lif activity, treating immune disorders and diseases, and stimulatings immune responses
CN102167742B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗her2单克隆抗体、其制备方法及用途
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
TWI486172B (zh) 2013-11-08 2015-06-01 長庚大學 鼻咽癌治療的醫藥

Also Published As

Publication number Publication date
LT2556091T (lt) 2016-12-27
EP2556091A1 (en) 2013-02-13
KR102294207B1 (ko) 2021-08-26
AU2011237922B2 (en) 2014-07-10
KR20180078352A (ko) 2018-07-09
EP2371860A1 (en) 2011-10-05
KR20200119344A (ko) 2020-10-19
EA202092276A3 (ru) 2021-04-30
HUE030578T2 (en) 2017-06-28
IL241952A (en) 2017-10-31
MX2012011636A (es) 2013-04-03
BR112012025517B1 (pt) 2021-08-31
US10968273B2 (en) 2021-04-06
EA201201373A1 (ru) 2013-04-30
SI2556091T1 (sl) 2017-02-28
CY1119451T1 (el) 2018-03-07
EA036698B9 (ru) 2021-02-25
SMT201600468T1 (it) 2017-03-08
JP6289906B2 (ja) 2018-03-07
ES2608699T3 (es) 2017-04-12
SG184429A1 (en) 2012-11-29
KR20130121679A (ko) 2013-11-06
MX365054B (es) 2019-05-21
JP6483059B2 (ja) 2019-03-13
US20130142808A1 (en) 2013-06-06
EA036698B1 (ru) 2020-12-09
JP2013523796A (ja) 2013-06-17
EP3045473A1 (en) 2016-07-20
JP2017019775A (ja) 2017-01-26
IL222270A0 (en) 2012-12-31
AU2011237922A1 (en) 2012-11-01
HK1180702A1 (zh) 2013-10-25
US20190119373A1 (en) 2019-04-25
KR20190061098A (ko) 2019-06-04
CN103797031A (zh) 2014-05-14
EP2556091B1 (en) 2016-09-28
IL222270A (en) 2016-06-30
HK1208469A1 (en) 2016-03-04
KR20170125137A (ko) 2017-11-13
HK1223384A1 (en) 2017-07-28
RS55539B1 (sr) 2017-05-31
CA2797257A1 (en) 2011-10-13
IL254664B (en) 2022-03-01
PT2556091T (pt) 2017-01-03
EA202092276A2 (ru) 2021-01-29
CN109320609A (zh) 2019-02-12
HRP20161736T1 (hr) 2017-02-10
US8926956B2 (en) 2015-01-06
US20150139989A1 (en) 2015-05-21
BR112012025517A2 (pt) 2017-11-28
WO2011124566A1 (en) 2011-10-13
DK2556091T3 (en) 2017-01-16
IL254664A0 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
LT2556091T (lt) Antikūnas, atpažįstantis žmogaus leukemijos slopinantį faktorių (lif), ir anti-lif antikūnų naudojimas ligų, susijusių su nepageidaujama ląstelių proliferacija, gydymui
CY2019008I1 (el) Χρηση τροποποιημενων απο χιμαιρικο αντιγονικο υποδοχεα τ κυτταρων στη θεραπευτικη αγωγη καρκινου
EP3043819A4 (en) Anti-vstm5 antibodies and the use thereof in therapy and diagnosis
SG178991A1 (en) Anti-gitr antibodies
IL228813B (en) A polypeptide containing a first and second immunoglobulin each containing a single variable site and its use in the treatment of diseases
IL231449A0 (en) Humanized tissues for in-vitro research uses, their arrays, and methods for their production
ZA201307641B (en) Human tissue factor antibody and uses thereof
IL216283A0 (en) Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
IL236664B (en) Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
WO2011126864A3 (en) Cancer treatment with recombinant vector
IL212066A0 (en) Anti cxcr4 antibodies and their use for the treatment of cancer
IL236070A0 (en) The intraxten-hgh protein and its use in the treatment of growth hormone deficiency
SI2606120T1 (sl) Človeške facilitacijske celice in njihova uporaba
PL2580240T4 (pl) Przeciwciała s100a4 i ich terapeutyczne zastosowania
PL2700708T3 (pl) Zwiększanie zdolności limfocytów T do stymulacji ludzkiego antygenu prezentującego komórki in vitro oraz in vivo i jego zastosowanie w szczepieniu
ZA201204423B (en) Neuregulin antagonists and use thereof in treating cancer
EP2598164A4 (en) PERIPHERAL BLOOD SPARC ANTIBODIES AND USES THEREOF
PL2668205T3 (pl) Peptydy pochodzące z ludzkiej laktoferyny i ich zastosowanie
HK1206984A1 (en) Combination therapy of anti-mif antibodies and glucocorticoids
IL233080B (en) Bisarylsulfonamides used to treat inflammation and cancer
HK1206985A1 (en) Combination therapy of anti-mif antibodies and chemotherapeutics
EP3052109B8 (en) Therapy with cells from human placenta and hematopoietic cells
DK2665746T3 (en) Antibodies against the s100p protein for the treatment and diagnosis of cancer
IL219034A0 (en) Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer
AU344548S (en) Guitar in the shape and features of the guitar headstock and body